CLICK HERE to learn more about Kineta's reverse merger with NASDAQ listed Yumanity Therapeutics (YMTX) announcement

Kineta Inc.

  • about
    • company
    • team
    • board
    • SAB
  • platform
  • pipeline
    • KVA12.1
    • CD27
    • KCP506
    • LHF535
  • partnering
  • investors
  • news
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean
logo

KVA12.1
LEARN MORE VISTA blocking cancer therapy
LEARN MORE Building next-generation
cancer immunotherapies
LEARN MORE PiiONEERâ„¢ Innate immunity-focused
development platform

Kineta News

June 17, 2022
Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit

>>

June 17, 2022

Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit

June 7, 2022
Puget Sound Business Journal: Seattle biotech Kineta to go public in reverse merger deal with Yumanity Therapeutics

>>

June 7, 2022

Puget Sound Business Journal: Seattle biotech Kineta to go public in reverse merger deal with Yumanity Therapeutics

June 6, 2022
GeekWire: Seattle biotech Kineta will go public in deal with neurosciences company Yumanity Therapeutics

>>

June 6, 2022

GeekWire: Seattle biotech Kineta will go public in deal with neurosciences company Yumanity Therapeutics

 

 

 

 

 

 

 

join our email list

 

 

 

Kineta is a trademark of Kineta, Inc. ©2021 Kineta, Inc. Legal

Back to Top
English
English
Korean